ワシントンにおける膀胱癌の臨床試験
ワシントン内の拠点で、膀胱癌に関する25件の研究が参加者を募集しています。
ワシントン内の都市
公式研究テキスト（英語）
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT07061964A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
- University of Washington - Fred Hutchinson Cancer Center ( Site 0100), Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/01更新 · NCT06833073Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Valley Medical Center, Renton
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT03866382Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07667335Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
- Eye Associates Northwest - Edmonds Clinic, Edmonds
- Eye Associates Northwest - Kirkland Clinic, Kirkland
- Eye Associates Northwest - Ballard Clinic and Surgery Center, Seattle
- 他6件
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07421700A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Swedish Cancer Institute, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/28更新 · NCT07277413A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
- Fred Hutchinson Cancer Research Center ( Site 0787), Seattle
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/25更新 · NCT07419295Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- University of Washington Fred Hutchinson Cancer Center, Seattle
被験者募集中第1/2相
18歳〜99歳 · 全性別 · 2026/09/22更新 · NCT06814496A Home-Based Prehabilitation Exercise Intervention for Improving Physical Function in Patients With Bladder Cancer and Upper Tract Urothelial Cancer, Get Moving Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中
18歳以上 · 全性別 · 2026/09/10更新 · NCT06040762Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
- Spokane Urology, Spokane
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06567743The Vanguard Study: Testing a New Way to Screen for Cancer
- Madigan Army Medical Center, Tacoma
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Providence Regional Cancer System-Aberdeen, Aberdeen
- PeaceHealth Saint Joseph Medical Center, Bellingham
- Providence Regional Cancer System-Centralia, Centralia
- 他19件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/09/02更新 · NCT05334069Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT07579195Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
- Spokane Urology, Spokane
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/24更新 · NCT05951179Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中観察研究健康なボランティア歓迎
18歳以上 · 男性 · 2026/08/06更新 · NCT01050504Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中観察研究
18歳以上 · 全性別 · 2026/07/31更新 · NCT07225127Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- Local Institution - 0200, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/07/29更新 · NCT07106762A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
- University of Washington School of Medicine, Seattle
被験者募集中第2相
8歳以上 · 全性別 · 2026/07/27更新 · NCT05503797An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
- Research Site, Seattle
- Research Site, Tacoma
被験者募集中第3相
18歳以上 · 全性別 · 2026/07/22更新 · NCT07720284A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- Harborview Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
被験者募集中第2相
18歳以上 · 全性別 · 2026/07/22更新 · NCT04879329A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Northwest Medical Specialities. PLLC, Bonney Lake
- Swedish Cancer Institute - Edmonds Campus, Edmonds
- Swedish Cancer Institute Edmonds Campus, Edmonds
- 他9件
被験者募集中第1相
18歳以上 · 全性別 · 2026/07/06更新 · NCT04389632Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
- Fred Hutch/University of Washington Cancer Consortium, Seattle
被験者募集中
18歳以上 · 全性別 · 2026/07/06更新 · NCT07302230A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- Fred Hutchinson Cancer Center, Seattle
被験者募集中第1相
18歳以上 · 全性別 · 2026/02/13更新 · NCT06778863Blue Light Cystoscopy With Cysview® Registry
- University of Washington Medicine, Seattle
被験者募集中観察研究
18歳以上 · 全性別 · 2025/12/18更新 · NCT02660645SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Seattle
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。